|
|
Issuer: Immunic AG
/ Key words: Quarter Results/Quarterly / Interim Statement
Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update
08.05.2024 / 12:30 CET/CEST
The issuer is solely responsible for the content of this announcement.
Immunic, Inc. Reports First Quarte... Lire le communiqué |
|
| |
|
| |
|
|
Issuer: Immunic AG
/ Key words: Conference
Immunic to Participate in Investor and Scientific Conferences in May
06.05.2024 / 12:30 CET/CEST
The issuer is solely responsible for the content of this announcement.
Immunic to Participate in Investor and Scientific Conferences in May... Lire le communiqué |
|
| |
|
| |
|
|
Issuer: Immunic AG
/ Key words: Scientific publication
Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in RRMS in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation
30.04.2024 / 12:30 CET/CEST
The issuer is solely responsible for the content of this... Lire le communiqué |
|
| |
|
| |
|
|
Issuer: Immunic AG
/ Key words: Conference
Immunic to Host MS R&D Day and Participate in Investor Conferences in April
04.04.2024 / 12:30 CET/CEST
The issuer is solely responsible for the content of this announcement.
Immunic to Host MS R&D Day and Participate in Investor Conferences i... Lire le communiqué |
|
| |
|
| |
|
|
Issuer: Immunic AG
/ Key words: Patent
Immunic Receives Notice of Allowance for CompositionofMatter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States
20.03.2024 / 11:30 CET/CEST
The issuer is solely responsible for the content of this announcement.
Immunic Receives... Lire le communiqué |
|
| |
|
| |
